Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Evaluating the response of 3 dose levels of arimoclomol on various pharmacodynamic biomarkers in blood and cerebrospinal fluid as indicators of enhanced GBA in Gaucher Disease Type 1 or 3.
Epistemonikos ID: ca505496cff484f2b57f8105583e49c518870eaf
First added on: May 21, 2024